Abstract: A vehicle body fastener structure includes: a vehicle body frame on a vehicle body; a sub-frame including an attachment portion attached to the vehicle body frame; a welding pipe nut coupled to the vehicle body frame; and a bolt fastening the attachment portion to the welding pipe nut. The welding pipe nut includes a pipe inserted through the vehicle body frame and having a female thread, and a coupling flange provided at a base of the pipe and coupled to the vehicle body frame. The attachment portion is fastened to the welding pipe nut with the bolt threaded into the female thread, the coupling flange is coupled to the vehicle body frame. A boss protrudes from a surface of the coupling flange. A seat surface is provided on an end surface of the boss. The attachment portion abuts against the seat surface and is fastened with the bolt.

Abstract: A vehicle-body frame structure including a floor tunnel includes a cross member floor front and a transmission cross member. The cross member floor front is disposed at a vehicle front end of the floor tunnel and has a vehicle-widthwise cross-sectional shape that includes a first slant, a second slant and a third slant. The first slant extends from the vehicle bottom part toward an inward-and-upward side in a vehicle width direction of the vehicle. The second slant extends from a vehicle upper part of the first slant toward an outward-and-upward side in the vehicle width direction. The cross member floor front is formed by joining to each other members divided in a vehicle up-down direction of the vehicle on a vehicle upper side of the second slant. The transmission cross member is fixed to the cross member floor front on a vehicle upper side of the first slant.

Abstract: A fixing structure for a pipe nut includes a pipe nut main body, a first stopper, and a second stopper. A female screw portion is provided inside of the pipe nut main body, and the pipe nut main body penetrates a vehicle body frame having a hollow cross section. The first stopper is provided at a base end of the pipe nut main body and abuts on an outer surface of the vehicle body frame to restrict movement of the pipe nut main body in a longitudinal direction. The second stopper is provided on the pipe nut main body and abuts on a surface of the vehicle body frame different from the outer surface of the vehicle body frame on which the first stopper abuts, and the second stopper restricts movement of the pipe nut main body in the longitudinal direction.

Abstract: A vehicle body fastener structure includes: a vehicle body frame on a vehicle body; a sub-frame including an attachment portion attached to the vehicle body frame; a welding pipe nut coupled to the vehicle body frame; and a bolt fastening the attachment portion to the welding pipe nut. The welding pipe nut includes a pipe inserted through the vehicle body frame and having a female thread, and a coupling flange provided at a base of the pipe and coupled to the vehicle body frame. The attachment portion is fastened to the welding pipe nut with the bolt threaded into the female thread, the coupling flange is coupled to the vehicle body frame. A boss protrudes from a surface of the coupling flange. A seat surface is provided on an end surface of the boss. The attachment portion abuts against the seat surface and is fastened with the bolt.

Abstract: Provided is a work management system. The work management system manages an operating status of a tool of a worker and includes: a target object arranged on a tool; and a sensor capable of detecting the target object. The target object is movable such that it faces the sensor.

Abstract: Provided is a pharmaceutical composition for oral administration in which the solubility and/or dissolution properties of enzalutamide are improved and supersaturation is maintained. Also provided is a pharmaceutical composition for oral administration in which the oral absorbability of enzalutamide is improved. The pharmaceutical composition for oral administration comprises enzalutamide and polyvinyl alcohol.

Abstract: A vehicle-body frame structure including a floor tunnel includes a cross member floor front and a transmission cross member. The cross member floor front is disposed at a vehicle front end of the floor tunnel and has a vehicle-widthwise cross-sectional shape that includes a first slant, a second slant and a third slant. The first slant extends from the vehicle bottom part toward an inward-and-upward side in a vehicle width direction of the vehicle. The second slant extends from a vehicle upper part of the first slant toward an outward-and-upward side in the vehicle width direction. The cross member floor front is formed by joining to each other members divided in a vehicle up-down direction of the vehicle on a vehicle upper side of the second slant. The transmission cross member is fixed to the cross member floor front on a vehicle upper side of the first slant.

Abstract: In a pharmaceutical composition for oral administration comprising 6-(4,4-dimethylcyclohexyl)-4-[(1,1-dioxo-1?6-thiomorpholin-4-yl)methyl]-2-methylthieno[2,3-d]pyrimidine or a pharmaceutically acceptable salt thereof, a stable pharmaceutical composition for oral administration with rapid drug dissolution properties is provided. The pharmaceutical composition for oral administration contains a water-swellable substance, which is a polymer compound obtained by condensation polymerization of ?-glucose, a polymer compound obtained by condensation polymerization of ?-glucose, or a polymer compound having a pyrrolidone functional group.

Abstract: A mobile carriage includes a traveling part, a wheel, a bed, a displacement conversion part, and an elastic member. The wheel is provided on the traveling part. The bed is supported by the traveling part to be movable in a traveling direction of the traveling part. The displacement conversion part displaces the wheel relative to the traveling part in accordance with displacement of the bed relative to the traveling part. The elastic member applies a force to return the bed having moved relative to the traveling part to an initial position before the movement. The displacement conversion part displaces the wheel relative to the traveling part in a direction of inertial force acting on the bed.

Abstract: Disclosed is a test instrument for measuring an analyte in a liquid sample by a noble metal colloid aggregation measurement method. The test instrument involves a reaction chamber in which at least the liquid sample is to be reacted with a reagent, wherein the reagent is adhered on at least a part of a surface constituting the reaction chamber in a dried state, and the reagent enables the measurement of the analyte by a noble metal colloid aggregation measurement method.

Abstract: Provided is a pharmaceutical composition for oral administration in which the solubility and/or dissolution properties of enzalutamide are improved and supersaturation is maintained. Also provided is a pharmaceutical composition for oral administration in which the oral absorbability of enzalutamide is improved. The pharmaceutical composition for oral administration comprises enzalutamide and polyvinyl alcohol.

Abstract: Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.

Abstract: Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.

Abstract: Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.

Abstract: An autoantibody against Ku86 can be measured by reacting the autoantibody contained in a sample with a Ku86 antigen (which serves as a reagent) to produce an immune complex of the autoantibody and the Ku86 antigen and measuring the immune complex using a labeled anti-human immunoglobulin antibody. The measurement of the autoantibody enables the determination of primary hepatocellular carcinoma.

Abstract: Pentameric CRP is produced at a high efficiency by transferring DNA, which encodes monomeric CRP, into a silkworm to thereby construct a transgenic silkworm and then collecting and purifying pentameric CRP that is produced by the transgenic silkworm constructed above.

Abstract: Disclosed is an immunoassay method whereby a 5.9 kDa peptide which results from the degradation of the ?-E chain and ? chain of human fibrinogens and which is used as a peptide marker for diagnosing hepatic disease can be specifically assayed in a biological sample containing contaminating peptides by bringing antibodies that recognize the N terminal of said peptide marker and antibodies that recognize the C terminal of said peptide marker into contact with said peptide marker, forming immune complexes of said peptide marker and the two antibodies, and immunoassaying the obtained immune complexes.

Abstract: Pentameric CRP is produced at a high efficiency by transferring DNA, which encodes monomeric CRP, into a silkworm to thereby construct a transgenic silkworm and then collecting and purifying pentameric CRP that is produced by the transgenic silkworm constructed above.

Abstract: In the case of assaying the level of complex AB in a sample which likely contains the complex AB composed of substance A with another substance B, the complex is assayed by the competitive homogeneous assay method with the use of reagents including a reagent containing partner C specifically binding to substance A, a reagent containing partner D specifically binding to substance B, a reagent containing fine particles carrying substance A or an analog thereof and substance B or an analog thereof, and a reagent containing partner C specifically binding to substance A and partner D specifically binding to substance B. Thus, the complex in the sample can be easily assayed. The above method is applicable to general-purpose biochemical automatic analyzers.

Abstract: Pentameric CRP is produced at a high efficiency by transferring DNA, which encodes monomeric CRP, into a silkworm to thereby construct a transgenic silkworm and then collecting and purifying pentameric CRP that is produced by the transgenic silkworm constructed above.